Press Releases

Research and Markets: Key Findings from Treatment Algorithms: Parkinson's Disease

DUBLIN--(BUSINESS WIRE)-- Research and Markets ( has announced the addition of Decision Resources, Inc's new report "Key Findings from Treatment Algorithms: Parkinson's Disease" to their offering.

Parkinson's disease (PD) is one of the most common chronic neurodegenerative diseases in the elderly. Because PD is a progressive disease, the range and severity of symptoms in PD patients vary greatly during the course of the disease, as do complications inherently associated with some of the therapies used to treat PD symptoms.

Therefore, treatment goals change as PD patients progress from one stage of the disease to the next, resulting in a high rate of polypharmacy as therapies are added onto agents prescribed earlier in the course of the disease. In the early stages of the disease, treatment generally focuses on managing motor symptoms that are relatively mild in severity.

In the later stages, treatment focuses on achieving an optimal balance between managing more-severe motor symptoms through the use of levodopa (DuPont Pharma's Sinemet/Sinemet CR, other brands, generics) and minimizing motor response complications (MRCs) (e.g., motor fluctuations, dyskinesias) and/or psychotic symptoms (e.g., visual hallucinations) associated with the use of levodopa and other dopaminergic therapy. Also important is managing the other nonmotor symptoms such as dementia that often become more pronounced in advanced stages of PD.

Key Topics Covered:

1. Background

a) Publication Update

b) Report Contents and Features

c) Current Practice Guidelines

d) Key U.S. Market Events Influencing Treatment Selection

2. Key Findings for Newly Diagnosed Patients

a) Executive Summary

b) Graphical Views

3. Key Findings for Recently Treated Patients

a) Executive Summary

b) Graphical Views

4. Key Findings by Product

a) Mirapex ER and Pramipexole

b) Requip XL and Ropinirole

c) Mirapex ER and Pramipexole, Requip XL and Ropinirole

d) Azilect

e) Stalevo and Comtan

f) Donepezil

g) Exelon (patch) and rivastigmine

5. Appendix: Methodology

For more information visit

Source: Decision Resources, Inc

Research and Markets
Laura Wood, Senior Manager
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Healthcare and Medical Devices, Pharmaceuticals

Source: Research and Markets